Jade Biosciences, Inc. Stock-Based Compensation
Jade Biosciences, Inc. (JBIO) reported Stock-Based Compensation of $13.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-10
- Jade Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $13.61M, a 249.32% increase year-over-year.
- Jade Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $7.41M, a 205.61% increase year-over-year.
- Jade Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $9.40M, a 664.52% increase year-over-year.
- Jade Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $4.29M, a 114.43% increase year-over-year.
- Jade Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $20.01M, a 76.90% increase from fiscal 2024.
- Jade Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $11.31M, a 5.00% decline from fiscal 2023.
- Jade Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $11.91M, a 117.42% increase from fiscal 2022.
- Jade Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $5.48M, a 168.04% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $13.61M 10-Q · filed 2026-08-10 | $21.01M 10-Q · filed 2026-08-10 | $30.41M derived: sum of 3 quarters · filed 2026-08-10 | $34.70M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $7.41M 10-Q · filed 2026-05-07 | $16.80M derived: sum of 2 quarters · filed 2026-05-07 | $21.10M derived: sum of 3 quarters · filed 2026-05-07 | $24.99M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $9.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $13.69M derived: sum of 2 quarters · filed 2026-03-06 | $17.59M derived: sum of 3 quarters · filed 2026-08-10 | $20.01M 10-K · filed 2026-03-06 | |
| 2025-09-30 | $4.29M 10-Q · filed 2025-11-14 | $8.19M derived: sum of 2 quarters · filed 2026-08-10 | $10.61M 10-Q · filed 2025-11-14 | $11.84M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $3.90M 10-Q · filed 2026-08-10 | $6.32M 10-Q · filed 2026-08-10 | $7.55M derived: sum of 3 quarters · filed 2026-08-10 | $7.57M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $2.42M 10-Q · filed 2026-05-07 | $1.19M 10-Q · filed 2025-04-25 | $3.65M derived: sum of 2 quarters · filed 2026-05-07 | $3.68M derived: sum of 3 quarters · filed 2026-05-07 | $7.54M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.23M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | $1.26M 10-K · filed 2026-03-06 | $5.12M derived: sum of 3 quarters · filed 2026-03-06 | $11.31M 10-K · filed 2025-03-27 | |
| 2024-09-30 | $2.00M 10-Q · filed 2024-11-12 | $3.89M derived: sum of 2 quarters · filed 2025-11-14 | $10.07M 10-Q · filed 2024-11-12 | $11.34M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $3.87M 10-Q · filed 2024-08-12 | $8.06M 10-Q · filed 2024-08-12 | $11.32M derived: sum of 3 quarters · filed 2025-04-25 | $14.55M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-03-31 | $4.20M 10-Q · filed 2025-04-25 | $7.45M derived: sum of 2 quarters · filed 2025-04-25 | $10.69M derived: sum of 3 quarters · filed 2025-04-25 | $13.72M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2023-12-31 | $3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $6.49M derived: sum of 2 quarters · filed 2025-03-27 | $9.52M derived: sum of 3 quarters · filed 2025-03-27 | $11.91M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $3.24M 10-Q · filed 2024-11-12 | $6.27M derived: sum of 2 quarters · filed 2024-11-12 | $8.65M 10-Q · filed 2024-11-12 | $10.38M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $3.03M 10-Q · filed 2024-08-12 | $5.42M 10-Q · filed 2024-08-12 | $7.15M derived: sum of 3 quarters · filed 2024-08-12 | $8.65M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $2.38M 10-Q · filed 2024-05-13 | $4.11M derived: sum of 2 quarters · filed 2024-05-13 | $5.61M derived: sum of 3 quarters · filed 2024-05-13 | $6.84M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $3.23M derived: sum of 2 quarters · filed 2024-03-25 | $4.45M derived: sum of 3 quarters · filed 2024-03-25 | $5.48M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $1.50M 10-Q · filed 2023-11-13 | $2.72M derived: sum of 2 quarters · filed 2023-11-13 | $3.75M 10-Q · filed 2023-11-13 | $4.60M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $1.22M 10-Q · filed 2023-08-14 | $2.25M 10-Q · filed 2023-08-14 | $3.10M derived: sum of 3 quarters · filed 2023-08-14 | $3.95M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $1.02M 10-Q · filed 2023-05-15 | $1.88M derived: sum of 2 quarters · filed 2023-05-15 | $2.72M derived: sum of 3 quarters · filed 2023-05-15 | $3.04M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $854.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $1.70M derived: sum of 2 quarters · filed 2023-03-29 | $2.02M derived: sum of 3 quarters · filed 2023-03-29 | $2.04M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $845.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.17M derived: sum of 2 quarters · filed 2022-11-14 | $1.19M 10-Q · filed 2022-11-14 | $1.21M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $321.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $344.00K 10-Q · filed 2022-08-15 | $368.00K derived: sum of 3 quarters · filed 2022-08-15 | $389.00K derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $23.00K 10-Q · filed 2022-05-16 | $47.00K derived: sum of 2 quarters · filed 2022-05-16 | $68.00K derived: sum of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $45.00K derived: sum of 2 quarters · filed 2022-03-30 | $58.00K 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $34.00K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $13.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |